376,074 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Acquired by Sarasin & Partners LLP

Sarasin & Partners LLP purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 376,074 shares of the medical research company's stock, valued at approximately $187,134,000. Thermo Fisher Scientific comprises about 2.0% of Sarasin & Partners LLP's investment portfolio, making the stock its 23rd biggest holding. Sarasin & Partners LLP owned approximately 0.10% of Thermo Fisher Scientific as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in TMO. Bernard Wealth Management Corp. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $25,000. FPC Investment Advisory Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $28,000. Pillar Financial Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth about $29,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $30,000. Finally, Noble Wealth Management PBC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $35,000. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. Citigroup decreased their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. UBS Group dropped their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Finally, Scotiabank decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $605.30.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded up $6.00 during mid-day trading on Tuesday, hitting $414.53. The stock had a trading volume of 2,573,612 shares, compared to its average volume of 1,914,596. The company has a 50 day moving average of $419.12 and a two-hundred day moving average of $494.94. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a market cap of $156.48 billion, a PE ratio of 25.08, a PEG ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period in the prior year, the company earned $5.11 earnings per share. The firm's revenue was up .2% on a year-over-year basis. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.